NCT06037135 is a NA clinical trial of dexmedetomidine in Pheochromocytoma, sponsored by Yonsei University.

Who is sponsoring NCT06037135?

NCT06037135 is sponsored by Yonsei University.

What drugs are being tested in NCT06037135?

Interventions in NCT06037135: dexmedetomidine, 0.9% normal saline.

What condition does NCT06037135 study?

NCT06037135 studies Pheochromocytoma.

Is NCT06037135 still recruiting?

NCT06037135 is currently completed. Last updated 6 October 2023.

Last reviewed 2023-10-06 · How we verify

NCT06037135

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexmedetomidine Infusion During Laparoscopic Adrenalectomy

Completed NA Last updated 6 October 2023

What this trial tests

NA trial testing dexmedetomidine in Pheochromocytoma in 40 participants. Completed in 26 March 2021.

Timeline

3 December 2012

Primary endpoint
26 March 2021

26 March 2021

Quick facts

Lead sponsor	Yonsei University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	supportive care
Enrollment	40
Start date	3 December 2012
Primary completion	26 March 2021
Estimated completion	26 March 2021
Sites	1 location across South Korea

Drugs / interventions tested

dexmedetomidine (dexmedetomidine) — full drug profile →
0.9% normal saline

Conditions studied

Pheochromocytoma — all drugs for Pheochromocytoma →

Sponsor

Yonsei University

Who can join

Adults 20 to 70, any sex, with Pheochromocytoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators planned this study to investigate the effects of dexmedetomidine administration on intraoperative hemodynamic stability in patients with pheochromocytoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Trial watch: dexmedetomidine in cancer therapy.
Carnet Le Provost K, Kepp O, Kroemer G, Bezu L. · · 2024 · cited 24× · PMID 38481729 · DOI 10.1080/2162402x.2024.2327143
The effects of perioperative dexmedetomidine infusion on hemodynamic stability during laparoscopic adrenalectomy for pheochromocytoma: a randomized study.
Kim Y, Yoo YC, Kim NY, Shin HJ, et al · · 2023 · cited 3× · PMID 38020150 · DOI 10.3389/fmed.2023.1276535

Verify or expand the search:

Other trials of dexmedetomidine

Trials testing the same drug.

NCT06853431 — Determination of ED50 and ED95 With Clinical Efficacy of Intranasal Dexmedetomidine Combined With Esketamine for Preoper · Phase 4 · recruiting
NCT06702488 — Dexmedetomidine and Magnesium Sulfate in the Reduction Cognitive Dysfunction in Geriatrics · Phase 1 · recruiting
NCT06636578 — Dexmedetomidine Ropivacaine Versus Plain Ropivacaine in Bilateral Pectoralis Nerve (PECS) Block · Phase 4 · recruiting
NCT07510217 — ERAS Approach for Post-Craniotomy Headache and Psychological Recovery · Phase 2 · completed
NCT06498700 — Intraoperative Subanesthetic Ketamine Versus Dexmedetomidine Infusion for Prevention of Post-traumatic Stress Disorder A · NA · enrolling by invitation

Other recruiting trials for Pheochromocytoma

Currently open trials in the same condition.

NCT06427798 — Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendoc · Phase 1, PHASE2 · recruiting
NCT07195500 — Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging · recruiting
NCT06573723 — Institutional Registry of Rare Diseases · recruiting
NCT06377033 — Using the EHR to Advance Genomic Medicine Across a Diverse Health System · NA · recruiting
NCT06444607 — Hereditary Pheochromocytoma Assessment of Tumour Immunologies · recruiting

Other Yonsei University trials

Trials by the same sponsor.

NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06037135 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yonsei University
Last refreshed: 6 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06037135.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing